The role of rifaximin therapy in patients with irritable bowel syndrome without constipation

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 4, 2011, Pages 461-464

  Schey, Ron ^a   Rao, Satish S C ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

gut flora; IBS without constipation; rifaximin

Indexed keywords

PLACEBO; RIFAXIMIN; GASTROINTESTINAL AGENT; RIFAMYCIN;

ABDOMINAL PAIN; ARTICLE; BREAST CANCER; CHOLECYSTITIS; CONSTIPATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IRRITABLE COLON; OUTCOME ASSESSMENT; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; FEMALE; IRRITABLE BOWEL SYNDROME; MALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ABDOMINAL PAIN; CONSTIPATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIFAMYCINS; TREATMENT OUTCOME;

EID: 79960775031     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.11.50     Document Type: Article

References (24)

1. Pimentel M, Lembo T, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N. Engl. J. Med. 364, 22-32 (2011).
2. Drossman DA. AGA technical review on irritable bowel syndrome. Gastroenterology 123(6), 2108-2131 (2002). (Pubitemid 35408332)
3. Camilleri M, Andresen V. Current and novel therapeutic options for irritable bowel syndrome management. Dig. Liver Dis. 41, 854-862 (2009).
4. Layer P, Andresen V. Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea. Aliment. Pharmacol. Ther. 31, 1155-1164 (2010).
5. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am. J. Gastroenterol. 98, 412-419 (2003). (Pubitemid 36232393)
6. Spiegel BM. Questioning the bacterial overgrowth hypothesis of IBS: an epidemiologic and evolutionary perspective. Clin. Gastroenterol. Hepatol. 6, 461-469 (2011).
7. Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 60(3), 334-340 (2011).
8. Reddymasu SC, Sostarich S, McCallum RW. Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? BMC Gastroenterol. 10, 23 (2010).
9. Debbia EA, Maioli E, Roveta S, Marchese A. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J. Chemother. 20(2), 186-194 (2008). (Pubitemid 351797058)
10. Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin. Investig. Drugs. 18(3), 349-358 (2009).
11. Chang JY, Talley NJ. Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment Trends Pharmacol. Sci. 31(7), 326-334 (2010).
12. Layer P, Andresen V. Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea. Aliment. Pharmacol. Ther. 31, 1155-1164 (2010).
13. Posserud, I, Stotzer, PO, Bjornsson, ES et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 56, 802-808 (2007). (Pubitemid 46854194)
14. Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta- analysis. Dig. Dis. Sci. 55(9), 2441-2449 (2010).
15. Choung RS, Ruff KC, Malhotra A et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment. Pharmacol. Ther. 33(9), 1059-1067 (2011).
16. Attar A, Flourie B, Rambaud J-C, Franchisseur C, Ruszniewski P, Bouhnik Y. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 117, 794-797 (1999). (Pubitemid 29468220)
17. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann. Intern. Med. 145, 557-563 (2006). (Pubitemid 46780934)
18. Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with rifaximin. World J. Gastroenterol. 15(21), 2628-2631 (2009).
19. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am. J. Gastroenterol. 104(4), 1033-1049 (2009).
20. Søndergaard B, Olsson J, Ohlson K, Svensson U, Bytzer P, Ekesbo R. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: A randomized, placebo-controlled trial. Scand. J. Gastroenterol. 46(6), 663-672 (2011).
21. Bardhan KD, Bodemar G, Geldof H et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 14, 23-34 (2000). (Pubitemid 30058157)
22. Camilleri M, Chey WY, Mayer EA et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch. Intern. Med. 161, 1733-1740 (2001). (Pubitemid 32679548)
23. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 58, 367-378 (2009).
24. Ford AC, Talley NJ, Spiegel BM et al. Effect of fiber, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 337, a2313 (2008).